What is the stepwise treatment plan for ulcerative colitis, including first‑line mesalamine, corticosteroids, immunomodulators, biologics, and surgery?

Ulcerative Colitis Treatment

Treatment Algorithm Based on Disease Severity

For mild-to-moderate ulcerative colitis, start with mesalamine (5-ASA) as first-line therapy, using 2-3 grams daily for extensive disease or rectal formulations for distal disease; escalate to high-dose mesalamine (>3 grams) plus rectal therapy if inadequate response, then add corticosteroids (prednisone or budesonide MMX) if still refractory, and for moderate-to-severe disease, consider early use of advanced therapies (biologics, JAK inhibitors, or S1P modulators) rather than gradual step-up, particularly in patients at high risk for disease progression. 1, 2

---

Mild-to-Moderate Disease: Stepwise Approach

First-Line: Mesalamine (5-ASA)

Extensive or left-sided disease:

• Start with standard-dose oral mesalamine 2-3 grams daily (once-daily dosing preferred for adherence) 2, 3
• Add rectal mesalamine to oral therapy for enhanced efficacy 2
• If suboptimal response: escalate to high-dose mesalamine (>3 grams daily) combined with rectal mesalamine 2

Distal disease (proctosigmoiditis/proctitis):

• Use mesalamine enemas or suppositories as preferred over oral therapy 2
• For proctitis specifically: mesalamine suppositories are the strongest recommendation 2
• If intolerant to rectal mesalamine: switch to rectal corticosteroid foam or enemas 2

Second-Line: Corticosteroids

When to escalate: If refractory to optimized oral and rectal 5-ASA therapy 2

• Add oral prednisone OR budesonide MMX 2
• Use corticosteroids only for short-term induction due to significant side effects 4
• Critical caveat: Corticosteroids are for induction only, never for maintenance therapy

---

Moderate-to-Severe Disease: Advanced Therapies

Early Advanced Therapy Strategy

The 2024 AGA guideline represents a paradigm shift: early use of advanced therapies is now suggested over traditional step-up from 5-ASAs in moderate-to-severe disease. 1

This approach prioritizes:

• Faster disease control
• Prevention of complications
• Improved long-term outcomes

Exception: Patients with less severe disease who prioritize safety over efficacy may reasonably choose gradual step-up with 5-ASA first 1

Advanced Therapy Options

TNF Antagonists:

• Infliximab, adalimumab, golimumab
• Use in combination with immunomodulator (thiopurine) for enhanced efficacy 1
• Infliximab + immunomodulator has moderate-quality evidence supporting combination therapy 1

Non-TNF Biologics:

• Vedolizumab (anti-integrin)
• Anti-IL therapies
• Preferred in: Older patients, those with cardiovascular risk factors, or higher infection/malignancy risk (lower infectious complications than TNF antagonists) 1

JAK Inhibitors:

• Important safety considerations: Higher risk of major adverse cardiovascular events and cancer compared to TNF antagonists in older adults with cardiovascular risk factors (smoking, prior cardiovascular disease) 1
• Avoid in women of childbearing age contemplating pregnancy (limited pregnancy safety data) 1
• FDA label restricts use to patients with prior TNF antagonist failure or intolerance 1

S1P Receptor Modulators:

• Avoid in women contemplating pregnancy (limited pregnancy safety data) 1

Immunomodulators

Thiopurines (azathioprine, 6-mercaptopurine):

• NOT recommended as monotherapy for induction in moderate-to-severe UC 1
• Suggested for maintenance of remission (typically after corticosteroid-induced remission) 1
• Primary role: combination therapy with TNF antagonists 1

Methotrexate:

• NOT recommended for induction or maintenance in UC 1

---

Combination vs. Monotherapy

TNF antagonists + immunomodulator combination is superior to monotherapy for infliximab (moderate-quality evidence) and adalimumab/golimumab (low-quality evidence) 1

For non-TNF biologics: No recommendation exists for combination therapy—insufficient evidence 1

---

De-escalation Strategies

In patients achieving corticosteroid-free remission for ≥6 months on combination therapy:

• Do NOT withdraw the TNF antagonist (conditional recommendation) 1
• Withdrawing immunomodulator: no clear recommendation (knowledge gap) 1
• Stop 5-ASAs in patients who escalated to immunomodulators or advanced therapies after 5-ASA failure 1
  • Exception: Patients with partial response may benefit from continuing 5-ASA, particularly those with residual proctitis who can add rectal 5-ASA 1

---

Therapy Selection: Key Clinical Considerations

Infection/malignancy risk: Choose vedolizumab or anti-IL therapies over TNF antagonists 1

Cardiovascular risk factors or older age: Avoid JAK inhibitors; prefer TNF antagonists or other biologics 1

Pregnancy planning: Avoid JAK inhibitors and S1P modulators 1

Multiple prior biologic failures: Lower-efficacy medications require longer treatment duration for response; observational data support infliximab and golimumab effectiveness even after prior advanced therapy exposure 1

---

Surgery

Indications for proctocolectomy:

• Treatment-refractory disease despite optimized medical therapy 4
• Detection of carcinoma or high-grade epithelial dysplasia 4
• Acute complications (toxic megacolon) 5

Surgery remains the only curative option when medical therapies fail 4, 5

---

Common Pitfalls to Avoid

1. Using corticosteroids for maintenance: Only for induction; transition to steroid-sparing agents 4
2. Delaying advanced therapies in moderate-to-severe disease: Early use prevents complications and improves outcomes 1
3. Inadequate mesalamine dosing: Use standard-dose (2-3 g) or high-dose (>3 g) with rectal therapy for optimal effect 2
4. Forgetting rectal therapy: Adding rectal mesalamine to oral therapy significantly improves outcomes in extensive/left-sided disease 2
5. Using thiopurine monotherapy for induction: Ineffective; reserve for maintenance or combination therapy 1
6. Continuing 5-ASAs after escalation: Stop in most patients who advance to immunomodulators/biologics (unless partial response with residual proctitis) 1